1https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf, Pfizer Inc. +1 (212) 733-3810[email protected], Array BioPharma Inc. For information on 2019 financial guidance, please see the press release for Pfizer’s Second Quarter 2019 Results here. Andrea N. Flynn, Ph.D. Pfizer and BioNTech Coronavirus Vaccine Accepted for Rolling Review in Canada, 3 Stocks That Are Absurdly Cheap Right Now, Copyright, Trademark and Patent Information. Additional Information and Where to Find It. The company has updated its 2019 financial guidance based on a number of factors, including this acquisition. For more information on Array, please visit http://www.ArrayBioPharma.com or follow @ArrayBioPharma on Twitter and LinkedIn. Under the terms of the merger agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all outstanding shares of Array common stock for $48 per share in cash for a total enterprise value of approximately $11.4 billion. Only time will tell if it was a smart one.

This release contains forward-looking information related to Pfizer, Array and the acquisition of Array by Pfizer that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Pfizer is paying $48 per Array share, which rose 60% to $47.38 in light premarket trading. Therapeutic Modalities and Technology Platforms, Small Molecule Product & Process Development, Maintaining Emotional Well-Being During COVID-19, Coronavirus disease (COVID-19) Scientific Resources, Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron, Creating Cures Through Facility Investments, https://www.webcaster4.com/Webcast/Page/748/30866, http://investor.ArrayBioPharma.com/sec-filings, https://investors.Pfizer.com/financials/sec-filings/default.aspx, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Announces Pricing of Upsized Initial Public Offering, Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma, Weitere Informationen über das Unternehmen, Secretary, Director & Chief Governance Counsel. For more than 150 years, we have worked to make a difference for all who rely on us. “Pfizer shares our commitment to patients and a passion for advancing science to develop even more options for individuals with unmet needs. 07.09.2020 → Meldung: BioNTech und Pfizer erhalten Genehmigung des Paul-Ehrlich-Instituts . Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Pfizer is paying $48 per share for Array, which closed 57% higher. That's a tougher question to answer. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
Pfizer said it expects to complete the deal in the second half of 2019. NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. But there's an even bigger opportunity for Braftovi and Mektovi in treating colorectal cancer. Patricia Kelly The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Array stock at no expense to them. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments. The good news is that the company can easily absorb a transaction of this size. Investor Relations: ARRAY STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ARRAY SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. But anyone looking for the Array acquisition to make a significant positive difference for Pfizer financially will have a long wait ahead. At the time the tender offer is commenced, Pfizer and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Array will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat … Array stock understandably skyrocketed in early trading on Monday. The products discussed herein may have different labeling in different countries. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Array arbeitet seit Jahren mit Pfizer bei der Entwicklung von Krebsmedikamenten zusammen. Pfizer said it expects to finance the majority of the deal, which has an enterprise value of about $11.4 billion, with debt and the remaining with existing cash. That is a type of cancer where the class of immunotherapies that include Merck and Co’s blockbuster Keytruda have not been as compelling as Array’s results, Morningstar analyst Damien Conover said. Array BioPharma joins with both a pair of targeted cancer drugs that could give Pfizer some immediate return for its money and a strong R&D engine with a track record of innovation. Computershare Trust Company, N.A., the depository and paying agent for the tender offer, has advised Pfizer that as of the tender offer expiration, 171,905,358 shares of Array common stock were validly tendered, representing approximately 77.0% of the shares outstanding. Forward-looking statements in this release and the accompanying call include, among other things, statements about the potential benefits of the acquisition, earnings dilution and accretion, and growth, Pfizer’s and Array’s plans, objectives, expectations and intentions, the financial condition, results of operations and business of Pfizer and Array, the BRAF/MEK combination and Array’s other pipeline and portfolio assets. For more than 150 years, we have worked to make a difference for all who rely on us. Chuck Triano Make no mistake: Pfizer is getting a couple of promising drugs in this deal. Pfizer expects to finance the majority of the transaction with debt and the balance with existing cash. Get this delivered to your inbox, and more info about our products and services. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in development, as well as a portfolio of out-licensed potentially best-in-class and/or first-in-class medicines, which are expected to generate significant royalties over time.

The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Data is a real-time snapshot *Data is delayed at least 15 minutes. See you at the top! Pfizer hatte zuletzt stark in sein Potfolio an neuen Krebsmedikamenten investiert, um drohende Umsatzausfälle durch den Patentverlust des Schmerzmittels Lyrica aufzufangen. Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon @themotleyfool #stocks $PFE $ARRY $LLY, understandably skyrocketed in early trading on Monday, reported positive results a few weeks ago, Got $500? Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. The largest U.S. drugmaker is paying a hefty premium of 62% to get access to Array's approved treatments for skin cancer as well as its other experimental drugs. All Rights Reserved. These results were so impressive that some analysts now predict that Array's Braftovi triplet will become the standard of care in treating colorectal cancer. Pfizer will pay around $48 per share in cash -- 63% above Array's Friday closing price -- for a total of around $11.4 billion. In light of that, some projections forecast the combo could approach blockbuster sales levels. But what was Pfizer thinking? Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer’s shares rose almost 0.3%. +1 (212) 733-3901[email protected], Media Relations: Pfizer (NYSE:PFE) is at it again. Patricia Kelly The buyout definitely expands Pfizer's oncology lineup into types of cancer where the company isn't very strong right now.

Reporting by Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Susan Thomas and Bill Berkrot. Participants are advised to pre-register in advance of the conference call. The information contained in this release is as of June 17, 2019. The triplet combination could be the first chemotherapy-free, targeted regimen for patients with BRAF-mutant mCRC. After a couple of years without any significant merger and acquisition activity, the big drugmaker announced on Monday that it's buying Array BioPharma (NASDAQ:ARRY).

As Array’s colleagues become part of Pfizer, the company plans to maintain Array’s operations in Cambridge, Massachusetts and Morrisville, North Carolina, as well as Boulder, Colorado, which becomes part of Pfizer’s Oncology Research & Development network in addition to La Jolla, California and Pearl River, New York. The largest U.S. drugmaker agreed to pay a hefty premium of 62% for Array, which sells the combination treatment Braftovi and Mektovi for melanoma. In 2021, the earnings impact is expected to be neutral. In the U.S., colorectal cancer is the third most common type of cancer in men and women. —Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term —Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough combination of BRAF/MEK inhibitors under investigation for a potential first-in-class therapy for patients with BRAF-mutant metastatic colorectal cancer —Expands Pfizer’s pipeline with multiple high-potential targeted investigational cancer therapies and adds a large portfolio of royalty-generating out-licensed medicines —Plans to maintain highly productive research unit in Boulder to complement Pfizer’s research hubs —Transaction valued at $48 per Array share in cash, for a total enterprise value of approximately $11.4 billion.